Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Neuroprotective effects of gelsolin during murine stroke
Matthias Endres, … , David J. Kwiatkowski, Michael A. Moskowitz
Matthias Endres, … , David J. Kwiatkowski, Michael A. Moskowitz
Published February 1, 1999
Citation Information: J Clin Invest. 1999;103(3):347-354. https://doi.org/10.1172/JCI4953.
View: Text | PDF
Article

Neuroprotective effects of gelsolin during murine stroke

  • Text
  • PDF
Abstract

Increased Ca2+ influx through activated N-methyl-D-aspartate (NMDA) receptors and voltage-dependent Ca2+ channels (VDCC) is a major determinant of cell injury following brain ischemia. The activity of these channels is modulated by dynamic changes in the actin cytoskeleton, which may occur, in part, through the actions of the actin filament–severing protein gelsolin. We show that gelsolin-null neurons have enhanced cell death and rapid, sustained elevation of Ca2+ levels following glucose/oxygen deprivation, as well as augmented cytosolic Ca2+ levels in nerve terminals following depolarization in vitro. Moreover, major increases in infarct size are seen in gelsolin-null mice after reversible middle cerebral artery occlusion, compared with controls. In addition, treatment with cytochalasin D, a fungal toxin that depolymerizes actin filaments, reduced the infarct size of both gelsolin-null and control mice to the same final volume. Hence, enhancement or mimicry of gelsolin activity may be neuroprotective during stroke.

Authors

Matthias Endres, Klaus Fink, Jinmin Zhu, Nancy E. Stagliano, Vimala Bondada, James W. Geddes, Toshifumi Azuma, Mark P. Mattson, David J. Kwiatkowski, Michael A. Moskowitz

×

Figure 7

Options: View larger image (or click on image) Download as PowerPoint
Infarct size and neurological deficits after cytochalasin D (cyto D) tre...
Infarct size and neurological deficits after cytochalasin D (cyto D) treatment following MCA occlusion/reperfusion. (a) Treatment with the actin-depolymerizing compound cyto D (0.1 and 1.0 μg intracerebroventricularly 10 min before ischemia) reduced infarct size after 2 h of filamentous MCA occlusion and 22 h of reperfusion compared with vehicle in 129/SV mice. Cerebral infarction volume was determined quantitatively as described; significant differences were also obtained when infarct sizes were corrected for brain swelling. Data are presented as mean and SE (n = 8–12 animals per group). *P < 0.05 vs. vehicle. Student's t test. (b) Neurological sensory-motor deficits were significantly reduced in cyto D–treated 129/SV mice compared with controls. Deficits were evaluated blindly using an established rating system from 0 (no deficit) to 3 (severe). Data are presented as mean and SE (n = 8–12 animals per group). *P < 0.05 vs. vehicle. Mann-Whitney rank sum test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts